Literature DB >> 9230206

Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes.

E M Evans1, S Man, A S Evans, L K Borysiewicz.   

Abstract

CTLs specific for high-risk human papillomaviruses (HPVs) have recently been found in the peripheral blood of cervical cancer patients. Although cell-mediated immunity is thought to be important in the control of HPV infection, the functional relevance and site of activation of HPV-specific CTLs are unclear. We identified HLA-A*0201-restricted HPV-16 E7 peptide-specific CTLs in the peripheral blood (four of five patients), draining lymph nodes (three of four patients) and tumors (one of three patients) of cervical cancer patients. In four of four cancer patients, the frequency of CTLs specific for a recombinant vaccinia virus expressing HPV-16 and -18 E6/E7 gene products was found to be higher in tumors and lymph nodes compared with that of peripheral blood. HPV-specific CTLs were not identified in any of seven healthy controls, but primary responses could be generated by peptide-pulsed dendritic cells (four of four controls). In a non-HLA-A*0201 subject with invasive carcinoma, other HLA alleles also presented HPV antigens. This is the first demonstration that virus-specific CTLs infiltrate the virus-associated tumor, where they may play an important role in restricting disease progression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9230206

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

Review 1.  Cell-mediated immune response to human papillomavirus infection.

Authors:  M Scott; M Nakagawa; A B Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

Review 2.  Human papillomavirus therapy for the prevention and treatment of cervical cancer.

Authors:  Samir N Khleif
Journal:  Curr Treat Options Oncol       Date:  2003-04

Review 3.  Vaccinations for Anal Squamous Cancer: Current and Emerging Therapies.

Authors:  John Berry; Sean C Glasgow
Journal:  Clin Colon Rectal Surg       Date:  2018-11-02

4.  Cytotoxic T-lymphocyte responses to human papillomavirus type 16 E5 and E7 proteins and HLA-A*0201-restricted T-cell peptides in cervical cancer patients.

Authors:  Dai-Wei Liu; Yuh-Cheng Yang; Ho-Fan Lin; Mei-Fang Lin; Ya-Wen Cheng; Chen-Chung Chu; Yeou-Ping Tsao; Show-Li Chen
Journal:  J Virol       Date:  2007-01-03       Impact factor: 5.103

5.  Induction of human papillomavirus type 16-specific immunologic responses in a normal and an human papillomavirus-infected populations.

Authors:  Wen-Fang Cheng; Chien-Nan Lee; Yi-Ning Su; Ming-Cheng Chang; Wen-Chun Hsiao; Chi-An Chen; Chang-Yao Hsieh
Journal:  Immunology       Date:  2005-05       Impact factor: 7.397

6.  CD4-positive and CD8-positive cytotoxic T lymphocytes contribute to human papillomavirus type 16 E6 and E7 responses.

Authors:  M Nakagawa; D P Stites; J M Palefsky; Z Kneass; A B Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  1999-07

Review 7.  Warts and all: human papillomavirus in primary immunodeficiencies.

Authors:  Jennifer W Leiding; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2012-10-01       Impact factor: 10.793

8.  Different methods of identifying new antigenic epitopes of human papillomavirus type 16 E6 and E7 proteins.

Authors:  Mayumi Nakagawa; Kevin H Kim; Anna-Barbara Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  2004-09

9.  Reversal of papilloma growth in rabbits therapeutically vaccinated against E6 with naked DNA and/or vesicular stomatitis virus vectors.

Authors:  Janet L Brandsma; Mark Shlyankevich; Yuhua Su; Daniel Zelterman; John K Rose; Linda Buonocore
Journal:  Vaccine       Date:  2009-07-15       Impact factor: 3.641

10.  Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors.

Authors:  Duane A Sewell; Zhen Kun Pan; Yvonne Paterson
Journal:  Vaccine       Date:  2008-08-03       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.